SRR934880
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- G2M_CHECKPOINT+0.602
- E2F_TARGETS+0.581
- MYC_TARGETS_V1+0.541
- MYC_TARGETS_V2+0.491
- MITOTIC_SPINDLE+0.468
- TGF_BETA_SIGNALING+0.387
- DNA_REPAIR+0.362
- UNFOLDED_PROTEIN_RESPONSE+0.343
- WNT_BETA_CATENIN_SIGNALING+0.341
- PROTEIN_SECRETION+0.272
Top 10 suppressed
- MYOGENESIS-0.450
- KRAS_SIGNALING_DN-0.424
- COAGULATION-0.396
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.363
- INFLAMMATORY_RESPONSE-0.345
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.345
- ESTROGEN_RESPONSE_LATE-0.340
- PANCREAS_BETA_CELLS-0.308
- XENOBIOTIC_METABOLISM-0.297
- APICAL_SURFACE-0.295
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 4938761D-0762-4984-A399-BC036D6D2140 | — | — | 0.958 |
| 2 | 0D1652B9-93F6-4D1A-BF06-B654663C92E3 | — | — | 0.946 |
| 3 | D902E43A-F384-432A-B690-D20BFCC78443 | — | — | 0.944 |
| 4 | SRR934879 | — | — | 0.941 |
| 5 | SRR934744 | — | — | 0.940 |
| 6 | C6A16A8F-0AB7-42E9-A068-15EECF2912D3 | — | — | 0.939 |
| 7 | 4FD9ED95-21E7-440D-AAA9-86DDDF12B37A | — | — | 0.936 |
| 8 | SRR934853 | — | — | 0.935 |
| 9 | 4A2E75AE-A92F-4497-9253-64AC42CFA745 | — | — | 0.931 |
| 10 | SRR934749 | — | — | 0.930 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 15 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| G2M_CHECKPOINT | 0.602 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.581 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.541 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.491 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.468 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.387 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.362 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.343 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.341 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.272 | Remibrutinib | — uncovered |
| NOTCH_SIGNALING | 0.227 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.121 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.083 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.030 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.002 | Inavolisib | — uncovered |